Business
-
Leyden Laboratories has announced a €20 million venture debt financing deal with the European Investment Bank, with funds intended to support development of Leyden Labs’ antiviral nasal sprays, including PanFlu. The investment falls under the… Read more . . .
-
Lupin has announced a new partnership with Honeywell and said that it will use Honeywell’s Solstice Air HFO-1234ze, a low global warming potential (LGWP) propellant, in Lupin metered dose inhalers. The announcement did not specify… Read more . . .
-
LTR Pharma announced a development agreement with Strategic Drug Solutions, Inc. for development of a nasal spray for the treatment of esophageal motility disorders (difficulty in swallowing). The Australian company says that the product will… Read more . . .
-
Vaccine developer Ethris, which recently received $5 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for development of spray-dried RNA vaccines for nasal delivery, has announced that EU4Health has awarded the company… Read more . . .
-
Akita Biosciences announced that a grant from Flu Lab will fund a pilot study of the company’s Profi prophylactic nasal spray in healthcare workers. Akita launched Profi, an OTC gel-forming drug-free nasal spray, in 2023… Read more . . .
-
Rein Therapeutics says that the US Patent and Trademark Office (USPTO) has recently granted US Patents No. 12,280,088 and No. 12,280,089, which cover the dry powder peptide formulation of the company’s lead candidate, LTI-03. Both of the new… Read more . . .
-
German biotech startup AATec Medical announced that it has raised €4 million prior to a series A financing, with the funds going to development of the company’s ATL-105 inhaled recombinant alpha-1 antitrypsin (AAT) for the… Read more . . .
-
Inhaled vaccine developer Ethris and CDMO Lonza have announced that Lonza will develop spray-dried formulations of Ethris mRNA-based vaccine candidates. Earlier this year, Ethris announced that it would receive $5 million from the Coalition for… Read more . . .
-
Chiesi Group announced that it will spend €430 million to construct a new manufacturing facility on a site that it has acquired in Nerviano, Italy. The site will produce metered dose inhalers with low global warming… Read more . . .
-
US-based Paratek Pharmaceuticals will acquire all outstanding shares of intranasal drug developer Optinose in a deal worth up to $330 million, the companies said. According to the announcement, both companies’ boards have approved the deal,… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland